| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 康泰生物前身系成立于1992年9月8日的康泰有限。2002年12月11日，康泰有限以经审计的净资产为基础整体变更为康泰生物。目前公司注册资本为36,900万元，法定代表人为杜伟民，公司注册地为深圳市南山区科技工业园科发路6号，目前生产经营地为深圳市南山区科技工业园科发路6号和北京市大兴区中关村科技园区大兴生物医药产业基地思邈路35号。 公司主营业务为人用疫苗的研发、生产和销售，在人用疫苗领域深耕30余年，已发展成为研发实力雄厚、产品布局丰富、产业规模领先、国际化进展显著的创新型生物制药企业，具备病毒疫苗、细菌疫苗、基因工程疫苗、结合疫苗、联合疫苗等产品的研发和生产能力，同时具备病毒载体、新型佐剂、核酸疫苗(mRNA等)等平台技术的产品开发能力。目前主要上市销售的产品有13价肺炎球菌多糖结合疫苗、无细胞百白破b型流感嗜血杆菌联合疫苗（四联苗）、冻干人用狂犬病疫苗（人二倍体细胞）、23价肺炎球菌多糖疫苗、重组乙型肝炎疫苗(酿酒酵母)、b型流感嗜血杆菌结合疫苗、吸附无细胞百白破联合疫苗、水痘减毒活疫苗等，另有两款新冠疫苗分别在国内、印度尼西亚获批紧急使用。公司产品种类涵盖免疫规划疫苗和非免疫规划疫苗，产品覆盖了31个省、自治区、直辖市。 公司拥有国内先进的疫苗研发中心，形成了以自主研发为主，合作开发和“引进、消化、吸收、再创新”为辅的研发模式，先后从海外引进了冻干人用狂犬病疫苗（人二倍体细胞）、Sabin株脊髓灰质炎灭活疫苗（Vero细胞）等世界领先的疫苗生产技术。公司注重产学研合作，聚焦疫苗创新研发及产业化路径，加强与科研院所、高校的合作，吸引优秀人才和技术资源，推动疫苗新技术领域的合作开发，为公司新产品的研发及产业化提供坚实的保障。 | ||||||||||||||||||||||||
| Main Business | 人用疫苗的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 杜伟民 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 陶瑾 | ||||||||||||||||||||||||
| Solicitors | 国浩律师（深圳）事务所 | ||||||||||||||||||||||||
| Auditors | 信永中和会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0755-26988558 | ||||||||||||||||||||||||
| Fax No | 0755-26988600 | ||||||||||||||||||||||||
| Website | www.biokangtai.com | ||||||||||||||||||||||||
| office@biokangtai.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 07/02/2017 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.180 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.090 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 8.192 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 12.703B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |